Accelerating Entrepreneurship

Microplate DX

Microplate Dx is revolutionising the treatment of drug-resistant bacterial infections by developing rapid diagnostic tests to accurately pinpoint the optimum antibiotic choice for patients in minutes.

Microplate

Problem

Antimicrobial resistance (AMR), the phenomenon whereby organisms evolve and stop responding to medicines, is one of the greatest threats facing humanity. There were an estimated 5 million AMR-associated deaths in 2019, and by 2050, AMR could kill more than cancer and diabetes combined. Currently available laboratory-based tests take up to 48h to determine the optimum antibiotic for an infection, exacerbating AMR through ‘best-guess’ antibiotic prescribing and in some circumstances, can lead to severe health complications for patients and even death.

Solution

Microplate Dx are developing a cost-effective, easy-to-use, rapid diagnostic test, enabling clinicians in just 30-40 minutes, to select the best antibiotic for an infection (e.g. urinary tract infections, sepsis, fungal infections etc.), giving clinicians confidence in their treatment options. Working with global partners including manufacturers and clinicians, our mission is to eliminate best-guess antibiotic prescribing and deaths from AMR. Microplate Dx’s AI algorithms not only help individual patients, but society at large, as emerging resistance threats can be detected early.

Links

Website

LinkedIn

Twitter